Concepedia

Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.

Patrizia Tosi, Elena Zamagni, Claudia Cellini, Sonia Ronconi, Francesca Patriarca, Filippo Ballerini, Pellegrino Musto, Francesco Di Raimondo, A Ledda, F. Lauria,

PubMed · 2002 · 111 citations · 22 references

Abstract

These data confirm that thalidomide is active in patients with advanced relapsed/refractory MM and represent the basis for ongoing clinical trials aimed at testing the role of this drug as front line therapy for newly diagnosed disease.

References

22

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Seema Singhal, Jayesh Mehta, Raman Desikan et al. · New England Journal of Medicine · 1999 · 2.6K citations · Full text

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

Michel Attal, Jean‐François Rossi, Philippe Casassus et al. · New England Journal of Medicine · 1996 · 2.6K citations · Full text

Thalidomide is an inhibitor of angiogenesis.

Robert J. D’Amato, Michael Loughnan, Evelyn Flynn et al. · Proceedings of the National Academy of Sciences · 1994 · 2.5K citations · Full text

, , +13

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.

E P Sampaio, Euzenir Nunes Sarno, Ruth Galilly et al. · The Journal of Experimental Medicine · 1991 · 1.2K citations · Full text

, , +22

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Faith E. Davies, Noopur Raje, Teru Hideshima et al. · Blood · 2001 · 901 citations